Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03421912 Completed - Colorectal Cancer Clinical Trials

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)

CICAFIX
Start date: February 16, 2018
Phase: N/A
Study type: Interventional

This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the head and neck, cancers colorectal or pulmonary

NCT ID: NCT03421782 Completed - Sedentary Lifestyle Clinical Trials

Fatigue Interventions in Cancer (Exercise Intervention)

Start date: February 26, 2018
Phase: Phase 2
Study type: Interventional

This randomized pilot phase II trial studies how well exercise intervention with or without internet-based cognitive behavior therapy works in reducing fatigue in participants with prostate cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Exercise intervention and internet-based cognitive behavior therapy may help to improve feelings of tiredness in participants with prostate cancer. The study originally included both prostate cancer and breast cancer participants, but due to low accrual of breast cancer participants, the breast cancer cohort was closed and the study continued with prostate cancer participants only.

NCT ID: NCT03421743 Completed - Clinical trials for Mycobacterium Infections, Nontuberculous

Pilot Trial of Inhaled Molgramostim in Nontuberculous Mycobacterial (NTM) Infection

OPTIMA
Start date: March 1, 2018
Phase: Phase 2
Study type: Interventional

The trial is an open-label, non-controlled, multicenter, pilot clinical trial of inhaled molgramostim (recombinant human Granulocyte-Macrophage Colony Stimulating Factor; rhGM-CSF) in subjects with persistent pulmonary Nontuberculous Mycobacterial (NTM) infection. Subject will be treated for 24-weeks with inhaled molgramostim and will be followed up for 12-weeks after end of treatment. The primary aim of the trial is to investigate the efficacy of inhaled molgramostim on NTM sputum culture conversion to negative.

NCT ID: NCT03421652 Completed - Clinical trials for Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Start date: April 24, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works with radiation therapy in treating patients with urothelial bladder cancer that has spread from its original site of growth to nearby tissues or lymph nodes and are ineligible for chemotherapy. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab and radiation therapy may work better in treating patients with urothelial bladder cancer.

NCT ID: NCT03421392 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT

SYMPATHIC
Start date: January 1, 2018
Phase:
Study type: Observational

Idiopathic thrombocytopenic purpura (ITP) is the most frequent auto-immune cytopenia. There is no specific biological marker and the diagnosis often results from the exclusion of other differential diagnoses, notably inherited thrombocytopenia. Recent studies have reported an original platelet destruction mechanism in ITP, by antibody-mediated desialylation of membrane proteins. The detection of platelet sialylation can be readily achieved using flow cytometry. This could provide a new biomarker of ITP, useful to ascertain a diagnosis of ITP and guide towards proper patient management.

NCT ID: NCT03421327 Completed - Huntington Disease Clinical Trials

Genetic Risk: Whether, When, and How to Tell Adolescents

Start date: September 1, 2017
Phase:
Study type: Observational

This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for Huntington's Disease, parent/child pairs at risk for hereditary cancer, and genetic counselors.

NCT ID: NCT03420937 Completed - Clinical trials for Postoperative Recovery

Deep Neuromuscular Block During General Anaesthesia in Robotic Surgery

Start date: June 2016
Phase: Phase 4
Study type: Interventional

The aim of this project is to show, whether the use of the deep neuromuscular block in certain laparoscopic robot-assisted surgery can positively influence main physiological functions compared to the use of standard neuromuscular block. Secondary outcome is to find out whether the targeted specific reversal of neuromuscular block by sugammadex improves and fastens the post-operative recovery of the patients.

NCT ID: NCT03420742 Completed - Clinical trials for Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Start date: June 26, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.

NCT ID: NCT03420469 Completed - Clinical trials for Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

Start date: June 5, 2018
Phase: Early Phase 1
Study type: Interventional

Primary objectives: 1. To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers 2. To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.

NCT ID: NCT03419962 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Greek NIS Spiolto ELLACTO

Start date: March 19, 2018
Phase:
Study type: Observational

Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations